Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Azulay, Orly
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a	Completed	3	407	Europe, Canada, US, RoW	Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir	Eiger BioPharmaceuticals	Hepatitis Delta Virus	10/22	03/23
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis	Recruiting	2	180	Europe, Canada, Japan, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Biliary Cholangitis, PBC	12/25	12/25
Marzeeq, Rana
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis	Recruiting	2	180	Europe, Canada, Japan, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Biliary Cholangitis, PBC	12/25	12/25